相关实验视频

Updated: May 24, 2025

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

在胰腺癌中预测存活时间的炎症标志物:系统性审查和元分析

Rinrada Worapongpaiboon¹, Noppachai Siranart², Patavee Pajareya¹

¹Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

|March 6, 2025

概括

中性细胞与淋巴细胞的比率 (NLR) 和血小板与淋巴细胞的比率 (PLR) 可以预测胰腺癌的结果. 较高的NLR和PLR表明各种胰腺疾病的生存率较差,恶性瘤风险增加.

科学领域:

在瘤学瘤学.
医学诊断医学诊断医学诊断
生物标志物生物标志物

背景情况:

在胰腺癌 (PC) 中预后的确定是具有挑战性的.
中性粒细胞与淋巴细胞的比率 (NLR) 和血小板与淋巴细胞的比率 (PLR) 是胃肠道癌症的确立预后因素.
在PC中NLR和PLR的预后值需要进一步阐明.

研究的目的:

调查NLR和PLR在预测胰腺管腺癌 (PDAC) 和胰腺神经内分泌瘤 (PNET) 的生存结果中的预后价值.
评估炎症标志物 (NLR,PLR) 在预测胰腺囊性瘤 (PCN) 恶性瘤方面的潜力.
分析NLR和PLR与胰腺癌转移风险的关联.

主要方法:

一项系统性审查和105项涉及20138名患者的研究的元分析.
对NLR和PLR进行研究,以预测PDAC和PNET的生存结果.
在PCN中预测恶性瘤的炎症标志物的评估.
基于瘤切除能力,标记器切断值和瘤位置的亚组分析.
使用随机效应模型对危险比率 (HRs) 和赔率比率 (ORs) 的聚合分析.

主要成果:

在PDAC中增加的NLR与较差的整体存活率 (OS),无进展存活率 (PFS) 和无复发存活率 (RFS) 相相关 (HRs 1.79-1.91).
在PDAC中增加的PLR与较差的OS和RFS相关 (HRs1.33,1.94).
在PNET中,高的NLR预测了较差的OS和RFS (HRs2.57,3.05).
在PCN中,NLR和PLR与恶性瘤有显著的关联 (OR 3.07,HR 2.42).

结论:

NLR和PLR是胰腺癌结果的有效预测者.
这些标记物具有评估PC治疗反应的潜力.
在晚期胰腺疾病中,NLR和PLR可以帮助识别用于额外治疗策略的候选人.

关键词:

中性粒细胞与淋巴细胞的比率.胰腺癌是一种胰腺癌.血小板与淋巴细胞的比率.幸存的生存方式

更多相关视频

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Published on: May 10, 2024

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...